Vascular inflammation is a stronger predictor of residual cardiovascular risk than LDL cholesterol level among statin-treated patients. This finding from a large analysis of contemporary trials points to a potential new standard of care for atherosclerosis.
CLEAR Outcomes: Bempedoic Acid Reduces Cardiovascular Events in Statin-Intolerant Patients
A 14,000-patient trial has shown that LDL cholesterol reduction with the non-statin therapy translates to a lower rate of cardiovascular death, heart attack, stroke or revascularization.
Dietary Supplements Don’t Stack Up to Low-Dose Statin Therapy for LDL-C Reduction
Despite marketing claims, none of six dietary supplements commonly used for lipid lowering significantly reduced LDL cholesterol versus placebo adults with elevated atherosclerotic risk, a new study finds.
Two Reasons Why LDL Cholesterol Management Isn’t as Settled as You May Think
Our experts review real-world strategies for patients with statin intolerance and an anticipated new therapy that doesn’t cause muscle symptoms.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
PCSK9s Post-FOURIER: Who Should Be Treated? (Video)
As the dust settles in the wake of the FOURIER trial results, how should we translate them into practice? Dr. Steven Nissen shares his thoughts on this, as well as PCSK9 inhibitor safety, in this two-minute video.